Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-versus-Host Disease
DOI:
https://doi.org/10.5281/zenodo.22274681Keywords:
Mesenchymal stromal cells; Graft-versus-host disease; Haematopoietic stem cell transplantation; Potency assay; Randomised controlled trialsAbstract
Background: Steroid-refractory acute graft-versus-host disease remains a lethal complication of allogeneic transplantation,
and mesenchymal stromal cells have been given for two decades on largely uncontrolled evidence.
Objective: To examine why single-arm series and randomised trials report irreconcilable response rates.
Methods: Narrative review of single-arm cohorts, randomised trials, mechanistic studies and regulatory decisions.
Findings: Single-arm studies reported 71% overall response in 55 patients and 83% at day 28 in 69 patients, whereas
randomised trials found day-28 complete response of 45% versus 46% placebo (192 treated) and 35% versus 30% (244
treated). Placebo arms fell inside the single-arm range.
Conclusions: The evidence supports immunomodulatory activity conditional on inflammatory licensing, but not the efficacy
implied by uncontrolled response rates. Function-based potency assays are required.
References
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., et al. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet, 363(9419): 1439-1441.
Ringdén, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lönnies, H., et al. (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation, 81(10): 1390-1397.
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P.D., Matteucci, P., et al. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99(10): 3838-3843.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F.C., Krause, D.S., et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8(4): 315-317.
Krampera, M., Cosmi, L., Angeli, R., Pasini, A., Liotta, F., Andreini, A., et al. (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24(2): 386-398.
Polchert, D., Sobinsky, J., Douglas, G.W., Kidd, M., Moadsiri, A., Reina, E., et al. (2008) IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. European Journal of Immunology, 38(6): 1745-1755.
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A.I., et al. (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2(2): 141-150.
François, M., Romieu-Mourez, R., Li, M., Galipeau, J. (2012) Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Molecular Therapy, 20(1): 187-195.
Galleu, A., Riffo-Vasquez, Y., Trento, C., Lomas, C., Dolcetti, L., Cheung, T.S., et al. (2017) Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Science Translational Medicine, 9(416): eaam7828.
de Witte, S.F.H., Luk, F., Sierra Parraga, J.M., Gargesha, M., Merino, A., Korevaar, S.S., et al. (2018) Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells, 36(4): 602-615.
Cheung, T.S., Bertolino, G.M., Giacomini, C., Bornhäuser, M., Dazzi, F., Galleu, A. (2020) Mesenchymal stromal cells for graft versus host disease: mechanism-based biomarkers. Frontiers in Immunology, 11: 1338.
Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., et al. (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. The Lancet, 371(9624): 1579-1586.
Muroi, K., Miyamura, K., Ohashi, K., Murata, M., Eto, T., Kobayashi, N., et al. (2013) Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. International Journal of Hematology, 98(2): 206-213.
Muroi, K., Miyamura, K., Okada, M., Yamashita, T., Murata, M., Ishikawa, T., et al. (2016) Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. International Journal of Hematology, 103(2): 243-250.
Bader, P., Kuçi, Z., Bakhtiar, S., Basu, O., Bug, G., Dennis, M., et al. (2018) Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transplantation, 53(7): 852-862.
Macías-Sánchez, M.M., Morata-Tarifa, C., Cuende, N., Cardesa-Gil, A., Cuesta-Casas, M.A., Pascual-Cascon, M.J., et al. (2022) Mesenchymal stromal cells for treating steroid-resistant acute and chronic graft versus host disease: a multicenter compassionate use experience. Stem Cells Translational Medicine, 11(4): 343-355.
Kebriaei, P., Isola, L., Bahceci, E., Holland, K., Rowley, S.D., McGuirk, J.P., et al. (2009) Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 15(7): 804-811.
Ball, L.M., Bernardo, M.E., Roelofs, H., van Tol, M.J.D., Contoli, B., Zwaginga, J.J., et al. (2013) Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. British Journal of Haematology, 163(4): 501-509.
Kurtzberg, J., Prockop, S., Teira, P., Bittencourt, H., Lewis, V., Chan, K.W., et al. (2014) Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biology of Blood and Marrow Transplantation, 20(2): 229-235.
Galleu, A., Milojkovic, D., Deplano, S., Szydlo, R., Loaiza, S., Wynn, R., et al. (2019) Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. British Journal of Haematology, 185(1): 89-92.
Kurtzberg, J., Abdel-Azim, H., Carpenter, P., Chaudhury, S., Horn, B., Mahadeo, K., et al. (2020) A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 26(5): 845-854.
Kebriaei, P., Hayes, J., Daly, A., Uberti, J., Marks, D.I., Soiffer, R., et al. (2020) A phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 26(5): 835-844.
Galipeau, J. (2013) The mesenchymal stromal cells dilemma - does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy, 15(1): 2-8.
Harris, A.C., Young, R., Devine, S., Hogan, W.J., Ayuk, F., Bunworasate, U., et al. (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biology of Blood and Marrow Transplantation, 22(1): 4-10.
Kurtzberg, J., Prockop, S., Chaudhury, S., Horn, B., Nemecek, E., Prasad, V., et al. (2020) Study 275: updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children. Biology of Blood and Marrow Transplantation, 26(5): 855-864.
Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., et al. (2020) Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. New England Journal of Medicine, 382(19): 1800-1810.
von Bahr, L., Sundberg, B., Lönnies, L., Sander, B., Karbach, H., Hägglund, H., et al. (2012) Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biology of Blood and Marrow Transplantation, 18(4): 557-564.
Moll, G., Alm, J.J., Davies, L.C., von Bahr, L., Heldring, N., Stenbeck-Funke, L., et al. (2014) Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells, 32(9): 2430-2442.
Chinnadurai, R., Rajan, D., Qayed, M., Arafat, D., Garcia, M., Liu, Y., et al. (2018) Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach. Cell Reports, 22(9): 2504-2517.
Galipeau, J., Sensébé, L. (2018) Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell, 22(6): 824-833.
Alsultan, A., Farge, D., Kili, S., Forte, M., Weiss, D.J., Grignon, F., et al. (2024) International Society for Cell and Gene Therapy Clinical Translation Committee recommendations on mesenchymal stromal cells in graft-versus-host disease: easy manufacturing is faced with standardizing and commercialization challenges. Cytotherapy, 26(10): 1132-1140.
Kadri, N., Amu, S., Iacobaeus, E., Boberg, E., Le Blanc, K. (2023) Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. Cellular and Molecular Immunology, 20(6): 613-625.
Galipeau, J., Krampera, M., Barrett, J., Dazzi, F., Deans, R.J., DeBruijn, J., et al. (2016) International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy, 18(2): 151-159.
